Sagimet Biosciences Inc (NASDAQ: SGMT) Is Rated A Buy By Analysts.

In the latest trading session, 37.2 million Sagimet Biosciences Inc (NASDAQ:SGMT) shares changed hands as the company’s beta touched 3.63. With the company’s most recent per share price at $3.16 changing hands around $0.39 or 14.08% at last look, the market valuation stands at $101.75M. SGMT’s current price is a discount, trading about -555.38% off its 52-week high of $20.71. The share price had its 52-week low at $2.13, which suggests the last value was 32.59% up since then. When we look at Sagimet Biosciences Inc’s average trading volume, we note the 10-day average is 0.33 million shares, with the 3-month average coming to 357.97K.

Analysts gave the Sagimet Biosciences Inc (SGMT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended SGMT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Sagimet Biosciences Inc’s EPS for the current quarter is expected to be -0.41.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Sagimet Biosciences Inc (NASDAQ:SGMT) trade information

Instantly SGMT is in green as seen in intraday trades today. With action 10.49%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -41.70%, with the 5-day performance at 10.49% in the green. However, in the 30-day time frame, Sagimet Biosciences Inc (NASDAQ:SGMT) is 2.60% up. Looking at the short shares, we see there were 2.07 million shares sold at short interest cover period of 5.15 days.

The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 47.33% from its recent market value. According to analyst projections, SGMT’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -89.87% plunge from its current level, while the stock would need to soar -89.87% for it to hit the projected low.

Sagimet Biosciences Inc (SGMT) estimates and forecasts

Data shows that the Sagimet Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -39.69% over the past 6 months, a 41.35% in annual growth rate that is considerably higher than the industry average of 17.80%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -16.23%. The 2024 estimates are for Sagimet Biosciences Inc earnings to increase by 44.74%.

SGMT Dividends

Sagimet Biosciences Inc is expected to release its next quarterly earnings report on 2024-Aug-14.

Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 14.11% of Sagimet Biosciences Inc shares while 70.10% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 81.61%.